|
REDHILL BIOPHARMA LTD.
|
|
|
|
(the "Registrant")
|
|
|
|
|
|
|
Date: March 30, 2022
|
By:
|
/s/ Dror Ben-Asher
|
|
|
Dror Ben-Asher
|
|
|
|
Chief Executive Officer
|
|
1. |
To appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s auditors for the year 2022 and for an additional period until the next Annual
General Meeting; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2021;
|
2. |
To approve the re-election of Mr. Dror Ben-Asher, Dr. Kenneth Reed and Ms. Alla Felder to the board of directors of the Company (the "Board of Directors") for an additional three-year term until the annual general meeting to be held in
2025;
|
3. |
To approve an amended Compensation Policy for a period of three years;
|
4. |
To approve an amendment to the Company's Letters of Exemption and Indemnification to the Company's officers and directors;
|
5. |
To approve a grant of restricted share units ("RSUs") each with respect to one American Depository Shares (each representing 10 ordinary shares, par value NIS 0.01 each) ("ADSs") of the Company to the non-executive directors of the
Company;
|
6. |
To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company’s Chief Executive Officer and Chairman of the Board of Directors;
|
7. |
To approve the grant of RSUs to Mr. Rick D. Scruggs, the Company’s Chief Commercial Officer and director; and
|
8. |
To approve an increase in the Company’s authorized share capital.
|
By Order of the Board of Directors,
|
|
Dror Ben-Asher
|
|
Chairman of the Board of Directors
|